FDA Recalls Calcipotriene Scalp Solution Due to Manufacturing Compliance Issues
Akorn, Inc. is recalling all lots of Calcipotriene Topical Solution 0.005% due to manufacturing compliance failures and incomplete stability studies. The manufacturer ceased operations before completing required stability tests.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The incomplete stability studies represent a risk-of-harm situation where the drug's safety and efficacy cannot be verified. Although no illnesses or injuries have been reported, the inability to confirm the medication's stability throughout its shelf life poses a potential safety concern.
Plain-English summary
Akorn, Inc. is recalling all lots of Calcipotriene Topical Solution, 0.005% (Scalp Solution), 60 mL bottles, distributed nationwide in the USA and Puerto Rico. The recall is due to current Good Manufacturing Practice (CGMP) deviations and incomplete stability studies.
The firm went out of business and could no longer continue the required stability studies. Stability data is essential to verify that a medication maintains its safety and effectiveness throughout its shelf life. The incomplete data means the drug's quality cannot be fully assured.
Consumers currently using this medication should contact their healthcare provider or pharmacist for guidance on alternative treatments. Do not discard medication in household trash or water; ask your pharmacist about proper disposal options.
The recalled product
- Product
- Calcipotriene Topical Solution, 0.005% (Scalp Solution), 60 mL bottles, Rx Only, Distributed by: Akorn Operating Company, LLC., Gurnee, IL 60031. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Topical medication
- Hazard
- cgmp-deviation
- incomplete-stability-testing
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27